Charta Health

Name: Charta Health
Brand: Charta Health

AI Native

AI Chart Review for Modern Healthcare Organizations

Est 2023|Valuation $125M|Raised $30.1M|5 Ref Customers

LinkedIn 10K|Web traffic 5K|FTEs 89|HQ San Francisco, California, US

01Competitive Landscape

Narrative analysis

- Charta vs AKASA: AKASA offers a broader set of RCM automation workflows, while Charta is more narrowly focused on chart screening and pre-bill compliance/coding accuracy. Buyers should map which workflows provide the highest ROI for their organization (coding, denials, prior authorization, claim status, correspondence, etc.). - Charta vs Fathom/CodaMetrix: Fathom and CodaMetrix present as coding automation platforms for large health systems. Charta differentiates itself by combining chart screening with compliance and clinical quality signals and by offering configurable remediation actions inside EHR workflows. - Incumbents (Optum and other large RCM vendors): Incumbents may be advantaged in enterprise procurement, established integrations, and services depth. Startups like Charta may offer more modern interfaces and faster iteration, but those benefits should be weighed against procurement and security requirements.

Market adoption trends

External reporting indicates growing interest and pilots for AI in revenue cycle functions. No Charta-specific market share or adoption numbers were available in public sources.

	Charta Health	AKASA	Fathom
Starting Price	Not public (demo/contract)	Not public (demo/contract)	Not public (consultation/demos for enterprise)
Most appropriate for	Provider organizations seeking automated pre-bill chart screening for revenue integrity, compliance, and clinical-quality signals	Health systems seeking broader RCM automation across multiple workflows	Health systems/RCM organizations seeking coding automation at scale
Key strength	Emphasis on increasing the share of encounters screened and providing multiple remediation action options (apply suggested changes, notify clinicians, or route for human review)	Broad revenue cycle automation portfolio and health-system focus	Focused coding automation with published performance narratives in certain settings
Key weakness	Limited public third-party reviews and limited publicly available security detail; vendor-provided ROI claims require validation	May be complex and oriented to large enterprise procurement; pricing not public	May be more narrowly focused on coding automation rather than broader compliance/quality chart review needs

01Competitive Landscape

Narrative analysis

Charta vs AKASA: AKASA offers a broader set of RCM automation workflows, while Charta is more narrowly focused on chart screening and pre-bill compliance/coding accuracy. Buyers should map which workflows provide the highest ROI for their organization (coding, denials, prior authorization, claim status, correspondence, etc.).
Charta vs Fathom/CodaMetrix: Fathom and CodaMetrix present as coding automation platforms for large health systems. Charta differentiates itself by combining chart screening with compliance and clinical quality signals and by offering configurable remediation actions inside EHR workflows.
Incumbents (Optum and other large RCM vendors): Incumbents may be advantaged in enterprise procurement, established integrations, and services depth. Startups like Charta may offer more modern interfaces and faster iteration, but those benefits should be weighed against procurement and security requirements.

Market adoption trends

External reporting indicates growing interest and pilots for AI in revenue cycle functions. No Charta-specific market share or adoption numbers were available in public sources.

	Charta Health	AKASA	Fathom
Starting Price	Not public (demo/contract)	Not public (demo/contract)	Not public (consultation/demos for enterprise)
Most appropriate for	Provider organizations seeking automated pre-bill chart screening for revenue integrity, compliance, and clinical-quality signals	Health systems seeking broader RCM automation across multiple workflows	Health systems/RCM organizations seeking coding automation at scale
Key strength	Emphasis on increasing the share of encounters screened and providing multiple remediation action options (apply suggested changes, notify clinicians, or route for human review)	Broad revenue cycle automation portfolio and health-system focus	Focused coding automation with published performance narratives in certain settings
Key weakness	Limited public third-party reviews and limited publicly available security detail; vendor-provided ROI claims require validation	May be complex and oriented to large enterprise procurement; pricing not public	May be more narrowly focused on coding automation rather than broader compliance/quality chart review needs

Charta Health

01Competitive Landscape

Narrative analysis

Market adoption trends

02Market Map

01Competitive Landscape

Narrative analysis

Market adoption trends

02Market Map